ELAN - Elanco Animal Health Incorporated

NYSE - NYSE Delayed price. Currency in USD
31.56
+0.42 (+1.35%)
At close: 4:03PM EST
Stock chart is not supported by your current browser
Previous close31.14
Open31.24
Bid0.00 x 900
Ask31.64 x 1300
Day's range31.04 - 31.83
52-week range25.25 - 35.46
Volume3,718,805
Avg. volume4,982,196
Market cap11.772B
Beta (5Y monthly)N/A
PE ratio (TTM)125.24
EPS (TTM)0.25
Earnings date18 Feb 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.88
  • Business Wire

    Elanco Confirms Date and Conference Call for 2019 Fourth Quarter Financial Results

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its 2019 fourth quarter financial results on Wednesday, February 19, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.

  • Business Wire

    Elanco Animal Health Announces Upsizing and Pricing of Common Stock and Pricing of Tangible Equity Unit Offerings

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. The common stock offering was upsized from the previously announced offering size of 19,159,866 shares of common stock. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT." The offerings are expected to close on January 27, 2020, subject to customary closing conditions.

  • Business Wire

    Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer’s Animal Health Business

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced it intends to make concurrent public offerings of 19,159,866 shares of its common stock and 11,000,000 tangible equity units, with an aggregate stated amount of $550 million for the units. Each tangible equity unit has a stated amount of $50 and is composed of (i) a prepaid stock purchase contract and (ii) a senior amortizing note due February 1, 2023 each issued by Elanco. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT."

  • Elanco (ELAN) Surges: Stock Moves 5.3% Higher
    Zacks

    Elanco (ELAN) Surges: Stock Moves 5.3% Higher

    Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • New Strong Sell Stocks for January 14th
    Zacks

    New Strong Sell Stocks for January 14th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Business Wire

    Elanco Signs Agreement with PetIQ to Divest Capstar®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement to divest the U.S. rights to Capstar®, an oral tablet that kills fleas in dogs and cats, to PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication and wellness company, for $95 million in an all-cash deal. The product had 2018 revenue of $28.5 million.

  • Business Wire

    Elanco Announces 2020 Financial Guidance

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced its initial financial guidance for 2020, including total revenue expectations in the range of $3.05 billion to $3.11 billion, and Core Revenue, which excludes strategic exits, in the range of $3.00 billion to $3.06 billion. Elanco also expects earnings per share (EPS) for 2020 to be in the range of $0.04 to $0.16 on a reported basis and $1.09 to $1.16 on an adjusted basis. These revenue and EPS expectations are for stand-alone Elanco only, including full year revenues for products that may be divested, and do not include any expected revenues from the Bayer animal health business or impact of transactions related to the acquisition, such as potential issuance of additional shares.

  • Business Wire

    Elanco Confirms Date for 2020 Financial Guidance Announcement

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its financial guidance for 2020 on Friday, January 10, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s financial guidance.

  • Business Wire

    Elanco Signs Agreement with Dechra to Divest Osurnia®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has signed an agreement to divest Osurnia®, a treatment for otitis externa in dogs, to Dechra Pharmaceuticals PLC (LON: DPH) for $135 million in an all-cash deal.

  • Business Wire

    Elanco to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET (9:30 a.m. PT).

  • Business Wire

    Elanco Sells Victoria, PEI, Canada R&D Facility to The Center for Aquaculture Technologies Canada (CATC)

    Elanco Animal Health Incorporated (NYSE: ELAN) has signed an agreement to sell its Victoria, Prince Edward Island (PEI) aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI.

  • Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
    Zacks

    Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

    Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

  • Business Wire

    Elanco Animal Health Receives Second Request from FTC Under HSR Act

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has received a second request for information from the U.S. Federal Trade Commission (FTC) in regards to its previously announced acquisition of Bayer AG’s (ETR: BAYN) animal health business. The request was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the review continues to progress as expected.

  • Business Wire

    Elanco Animal Health Appoints Chief Sustainability Officer, Emphasizes Continued Commitment to Advance Well-Being of Animals, People and Planet

    Elanco Animal Health Inc. (ELAN) today announced Sara Place, Ph.D., has joined the company as Chief Sustainability Officer, emphasizing the company’s continued commitment to make an impact on societal challenges by improving the health of animals. Place will join Elanco’s team of scientific experts: Chief Medical Officer Shabbir Simjee and Chief Animal Welfare Officer Michelle Calvo-Lorenzo. The group helps Elanco and its customers identify new opportunities to continue improving sustainable business practices, improve the well-being of animals and people, and reduce the environmental footprint of protein production by keeping food animals healthier.

  • Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
    Zacks

    Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

    Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

  • Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%
    Simply Wall St.

    Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • Business Wire

    Elanco Animal Health Reports Third Quarter Results

    GREENFIELD, Ind.-- -- Earnings per share was $0.03 , or $0.30 for the third quarter 2019, including a benefit of $0.02 from a tax item Gross margin improved to 53.3 percent of revenue , an improvement of 190 basis points and 210 basis points for the third quarter 2019 Total Revenue in the third quarter of 2019 increased 1 percent to $771.3 million; Total and Core Revenue grew 2 percent and 4 percent, ...

  • Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
    Zacks

    Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More

    Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.

  • Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline

    Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Elanco Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement

    Elanco Animal Health (ELAN) will announce its third-quarter 2019 financial results on Wednesday, November 6, 2019. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8 a.m. eastern time.

  • Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire
    Zacks

    Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire

    Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.

  • Based On Its ROE, Is Elanco Animal Health Incorporated (NYSE:ELAN) A High Quality Stock?
    Simply Wall St.

    Based On Its ROE, Is Elanco Animal Health Incorporated (NYSE:ELAN) A High Quality Stock?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Business Wire

    Elanco Advances Margin Expansion Journey with Business Restructuring

    Since its September 2018 initial public offering (IPO), Elanco Animal Health Inc. (ELAN) has continued to evaluate its capabilities, structure and staffing to meet its goal of being an agile, standalone company, focused exclusively on animal health and delivering on its Innovation, Portfolio and Productivity (IPP) strategy. As part of this effort, Elanco is implementing actions to enhance productivity and drive efficiency. Today’s proposed actions are another step in Elanco’s journey to build a stronger, more competitive animal health company.

  • Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
    Zacks

    Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

    Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more